Skip to main content

Advertisement

SpringerLink
Log in

Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Gitlin D, Perricelli A, Gitlin GM. Synthesis of -fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res. 1972;32(5):979–82.

    CAS  PubMed  Google Scholar 

  2. Purves LR, Bersohn I, Geddes EW. Serum alpha-feto-protein and primary cancer of the liver in man. Cancer. 1970;25(6):1261–70. https://doi.org/10.1002/1097-0142(197006)25:6<1261::AID-CNCR2820250603>3.0.CO;2-J.

    Article  CAS  PubMed  Google Scholar 

  3. Kinjo T, Taniguchi H, Kushima R, Sekine S, Oda I, Saka M, et al. Histologic and immunohistochemical analyses of alpha-fetoprotein—producing cancer of the stomach. Am J Surg Pathol. 2012;36(1):56–65. https://doi.org/10.1097/PAS.0b013e31823aafec.

    Article  PubMed  Google Scholar 

  4. Bourreille J, Metayer P, Sauger F, Matray F, Fondimare A. Existence of alpha-fetoprotein during gastric-origin secondary cancer of the liver. Presse Med. 1970;78(28):1277–8.

    CAS  PubMed  Google Scholar 

  5. McIntire KR, Waldmann TA, Moertel CG, Go VL. Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res. 1975;35(4):991–6.

    CAS  PubMed  Google Scholar 

  6. Chang YC, Nagasue N, Kohno H, Taniura H, Uchida M, Yamanoi A, et al. Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer. Am J Gastroenterol. 1990;85(11):1480–5.

    CAS  PubMed  Google Scholar 

  7. Chun H, Kwon SJ. Clinicopathological characteristics of alpha-fetoprotein-producing gastric cancer. J Gastric Cancer. 2011;11(1):23–30. https://doi.org/10.5230/jgc.2011.11.1.23.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Chang YC, Nagasue N, Abe S, Taniura H, Kumar DD, Nakamura T. Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol. 1992;87(3):321–5.

    CAS  PubMed  Google Scholar 

  9. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–49. https://doi.org/10.1056/NEJMra0706596.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581–611. https://doi.org/10.1210/er.2003-0027.

    Article  CAS  Google Scholar 

  11. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9. https://doi.org/10.1016/S0140-6736(13)61719-5.

    Article  CAS  Google Scholar 

  12. Arakawa Y, Tamura M, Aiba K, Morikawa K, Aizawa D, Ikegami M, et al. Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: a case report. Oncol Lett. 2017;14(3):3039–42. https://doi.org/10.3892/ol.2017.6514.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Bozkaya Y, Demirci NS, Kurtipek A, Erdem GU, Ozdemir NY, Zengin N. Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma. Mol Clin Oncol. 2017;7(2):267–74. https://doi.org/10.3892/mco.2017.1288.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H, et al. Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg. 2002;19(5):359–65. discussion 365

    Article  CAS  PubMed  Google Scholar 

  15. Hirajima S, Komatsu S, Ichikawa D, Kubota T, Okamoto K, Shiozaki A, et al. Liver metastasis is the only independent prognostic factor in AFP-producing gastric cancer. World J Gastroenterol. 2013;19(36):6055–61. https://doi.org/10.3748/wjg.v19.i36.6055.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Takahashi Y, Ohta T, Mai M. Angiogenesis of AFP producing gastric carcinoma: correlation with frequent liver metastasis and its inhibition by anti-AFP antibody. Oncol Rep. 2004;11(4):809–13.

    CAS  PubMed  Google Scholar 

  17. Kamei S, Kono K, Amemiya H, Takahashi A, Sugai H, Ichihara F, et al. Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein. J Gastroenterol. 2003;38(6):540–7. https://doi.org/10.1007/s00535-002-1099-y.

    Article  CAS  PubMed  Google Scholar 

  18. SY O, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, et al. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer. 2008;8(1):123. https://doi.org/10.1186/1471-2407-8-123.

    Article  CAS  Google Scholar 

  19. Chen LT, Oh DY, Ryu MH, Yeh KH, Yeo W, Carlesi R, et al. Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Res Treat. 2017;49(4):851–68. https://doi.org/10.4143/crt.2016.176.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780–7. https://doi.org/10.1200/JCO.2009.23.7537.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–70. https://doi.org/10.1016/S1470-2045(15)00050-9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan

    Jun Takada, Hiroshi Araki, Noritaka Ozawa, Tomohiko Sugiyama, Masaya Kubota, Takashi Ibuka & Masahito Shimizu

Authors
  1. Jun Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Araki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noritaka Ozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomohiko Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaya Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Ibuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahito Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Takada.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human Rights Statement and Informed Consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from the patient. Additional informed consent was obtained from the patient for which identifying information is included in this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takada, J., Araki, H., Ozawa, N. et al. Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature. J Gastrointest Canc 50, 556–559 (2019). https://doi.org/10.1007/s12029-017-0043-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-0043-6

Keywords

Search

Navigation